Drug Profile


Alternative Names: TEPADINA; Tepadina; Thioplex

Latest Information Update: 05 May 2017

Price : $50

At a glance

  • Originator ADIENNE
  • Class Antineoplastics; Myeloablative agonists; Organothiophosphorus compounds
  • Mechanism of Action Alkylating agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haematological disorders
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Adenocarcinoma; Cancer metastases; Graft-versus-host disease; Haematological disorders; Papilloma; Solid tumours

Most Recent Events

  • 27 Apr 2017 Thiotepa licensed to Amneal Pharmaceuticals in USA
  • 27 Apr 2017 Launched for Adenocarcinoma in USA (IV)
  • 27 Apr 2017 Launched for Cancer metastases in USA (Intraperitoneal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top